United States — Food and Drug Administration & Linda Marban
3 shared events · Importance 3 · Last updated Sep 03, 2026
Live sentiment trends, interaction importance charts, and action volume tracking available on the
Ergen Dashboard
Regulatory
United States — Food and Drug Administration: Regulator whose briefing documents and advisory committee vote triggered the stock collapse and legal actions.
Linda Marban: CEO who made positive statements about Deramiocel; now named in securities fraud lawsuits.
Jul 27, 2026 · 305 articles
Regulatory
United States — Food and Drug Administration: The United States — Food and Drug Administration's Cellular, Tissue, and Gene Therapies Advisory Committee is convening a meeting to review Paragon Therapeutics' Biologics License Application for Deramiocel, which is a critical step in the regulatory approval process for the drug.
Linda Marban: Linda Marban, CEO of Paragon Therapeutics, expressed confidence in the evidence supporting Deramiocel and emphasized the company's commitment to bringing the therapy to patients.
Jun 26, 2026 · 6 articles
Regulatory
United States — Food and Drug Administration: The FDA's July 27, 2026 briefing documents and July 29 advisory committee meeting triggered the stock collapse underlying the lawsuit, and its extension of the Deramiocel PDUFA date to November 22, 2026 keeps the review active.
Linda Marban: Capricor's CEO, whose positive statements about HOPE-3 and Deramiocel are cited in the complaint as materially misleading.
Aug 10, 2026 · 267 articles
ERGEN INTELLIGENCE
Explore this relationship live
Track how United States — Food and Drug Administration and Linda Marban interact across events, view sentiment trends, and discover connected entities.
Open Dashboard